Cagrilintide: Amylin Analogue Research Overview

September 28, 2026 · By My Store 3 Admin

Cagrilintide (INN: cagrilintide; Novo Nordisk development code AM833) is a long-acting synthetic analogue of amylin, a 37-amino acid peptide co-secreted with insulin by pancreatic beta cells. It is structurally distinct from the GLP-1 receptor agonist and GIP receptor agonist classes, operating through the amylin receptor system. This mechanistic distinction has generated research interest in Cagrilintide both as a standalone agent and in combination with semaglutide — the combination referred to in clinical development as CagriSema.

This article provides a research-focused overview of Cagrilintide’s molecular profile, amylin receptor mechanism, and published clinical data. All Bloom Vitality products are supplied strictly for in vitro laboratory and research use only.

Molecular Profile

Cagrilintide is a 37-amino acid analogue of human amylin with multiple amino acid substitutions designed to:

Prevent the amyloid aggregation that limits native amylin’s utility as a research and therapeutic agent
Confer resistance to enzymatic degradation, extending half-life
Incorporate a C18 fatty diacid moiety via a linker (analogous to the lipidation strategy used in semaglutide and Tirzepatide), enabling once-weekly dosing through albumin binding

These modifications distinguish Cagrilintide from pramlintide (the approved amylin analogue requiring multiple daily administrations), enabling a weekly dosing interval suitable for clinical development and research protocols.

Amylin Receptor Mechanism

Amylin acts at amylin receptors — heterodimers composed of the calcitonin receptor (CTR) complexed with receptor activity-modifying proteins (RAMPs 1, 2, or 3), forming AMY1, AMY2, and AMY3 receptor subtypes. Key proposed effects of amylin receptor activation include:

Satiety signalling — amylin acts centrally (primarily at the area postrema) to reduce food intake and promote satiety, independently of GLP-1 receptor signalling pathways
Gastric emptying modulation — amylin slows gastric emptying, contributing to postprandial glucose control
Glucagon suppression — amylin suppresses postprandial glucagon secretion
Body weight regulation — amylin has a well-established role in long-term body weight regulation in rodent models, operating via hypothalamic and brainstem circuits

The central amylin receptor mechanism is distinct from the GLP-1 receptor mechanism, operating through different neural circuits. This mechanistic complementarity is the primary scientific rationale for combining Cagrilintide with semaglutide.

CagriSema: Combination Research

The most significant clinical data for Cagrilintide comes from its investigation in combination with semaglutide (CagriSema). The Phase 2 COMBINE 1 trial published in The Lancet in 2023 (Enebo et al.) investigated CagriSema (2.4mg semaglutide + 2.4mg Cagrilintide, once weekly) in adults with obesity:

Mean body weight reduction of 15.6% at 32 weeks in the CagriSema group
Compared with 5.1% for Cagrilintide alone and 8.0% for semaglutide alone
Suggesting an additive effect beyond either component administered separately
Generally consistent tolerability with GLP-1 class effects (primarily gastrointestinal)

Phase 3 trials investigating CagriSema are ongoing under the REDEFINE programme. The REDEFINE 1 trial reported in early 2025 reported mean weight loss of approximately 22.7% at 68 weeks with CagriSema 2.4mg/2.4mg, though response rates were heterogeneous and results were considered below initial expectations by some analysts.

Standalone Cagrilintide Data

Phase 2 data for Cagrilintide as a standalone agent was published in The Lancet in 2021 (Enebo et al.), investigating doses from 0.3mg to 4.5mg once weekly over 26 weeks in adults with overweight or obesity:

Dose-dependent body weight reductions up to 10.8% at the highest dose
Favourable tolerability profile at research-relevant doses
Proof-of-concept for weekly amylin receptor agonism in a clinical setting

UK Research Context

Cagrilintide does not hold a marketing authorisation as a licensed medicine in the UK or any other jurisdiction as a standalone agent (as of September 2026). CagriSema combination development continues in Phase 3. Researchers in the UK working with Cagrilintide as a research compound should refer to the UK regulatory framework for research peptides for the relevant legislative context.

Comparison with Tirzepatide and Retatrutide

The three primary receptor targets in metabolic peptide research — GLP-1R, GIPR, and GCGR — are all distinct from the amylin receptor system. Cagrilintide’s amylin mechanism therefore represents a genuinely complementary approach rather than an incremental modification of the GLP-1 class, explaining the clinical interest in combination protocols. For comparison:

Tirzepatide — GLP-1R + GIPR dual agonist
Retatrutide — GLP-1R + GIPR + GCGR triple agonist
Cagrilintide — amylin receptor agonist (complementary, not overlapping)

Research Material

Bloom Vitality supplies Cagrilintide 10mg as a lyophilised research compound, independently third-party tested for purity and potency. Our Cagrilintide research material is part of the broader research peptides UK catalogue. Batch-specific Certificates of Analysis are available via our Certificates & Documentation page and Testing & Quality page.